Understanding and improving treatment for heparin-induced thrombocytopenia
New approaches to the pathophysiology, diagnosis and management of heparin-induced thrombocytopenia
This study is looking at a condition called heparin-induced thrombocytopenia (HIT) to help doctors tell the difference between harmful and harmless antibodies, so they can make better treatment choices and avoid giving patients unnecessary medications that might cause more bleeding.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10901956 on NIH RePORTER |
What this research studies
This research investigates heparin-induced thrombocytopenia (HIT), a serious condition where antibodies cause a dangerous drop in platelet levels. The team aims to differentiate between harmful and harmless antibodies that affect treatment decisions, which can lead to unnecessary use of alternative anticoagulants that may cause more bleeding. By isolating and characterizing these antibodies from patient samples, the researchers will develop new monoclonal antibodies and test their effects in a mouse model. This approach seeks to enhance diagnostic accuracy and treatment options for patients suffering from HIT.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with heparin-induced thrombocytopenia who are experiencing complications related to their condition.
Not a fit: Patients who do not have heparin-induced thrombocytopenia or those who are not receiving anticoagulant therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better diagnosis and safer treatment options for patients with heparin-induced thrombocytopenia.
How similar studies have performed: Previous research has shown promise in understanding antibody behavior in HIT, but this approach aims to provide novel insights and improvements in treatment.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Padmanabhan, Anand — Mayo Clinic Rochester
- Study coordinator: Padmanabhan, Anand
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.